Processa: PCS12852 Phase 2A improves gastric emptying (p<0.10); nine-month net loss $14.4M

Processa Pharmaceuticals, Inc.

PCS12852 Phase 2A: GEBT showed gastric emptying improvement for 0.5mg dose vs placebo (p<0.10); mild-to-moderate AEs, no serious events.
Net loss for nine months ended Sep 30, 2022: $14.4M ($0.90/share) vs $8.2M ($0.54/share) YoY.
Cash at Sep 30, 2022: $9.1M; expected to fund operations into Q3 2023.
R&D expenses rose to $8.3M (up $3.5M) due to ongoing clinical trials; G&A $6.1M (up from $3.4M).
Plans: Phase 2B trial for PCS12852 in 2023; NGC (PCS6422+capecitabine) Phase 2B planned after FDA meeting.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Processa Pharmaceuticals, Inc. reported for the nine months ended September 30, 2022 results: net income $14.4 million, EPS $0.90 per share.

Period: for the nine months ended September 30, 2022
Net income: $14.4 million
EPS: $0.90 per share
Result: reported results

Exact text from the filing

Our net loss for the nine months ended September 30, 2022, was $14.4 million or $0.90 per share

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Processa Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-030944

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.